Antibody Characterization
Our antibody characterization services are available as the next step in our service pipeline after antibody discovery and antibody production, as well as for investigators who want to characterize antibodies from existing cell lines.
Schedule With Us
To schedule antibody characterization services with the Antibody Technology shared resource, or to get more information about how we can work with you, fill out the inquiry form on our Rates and Scheduling page.
Using the iQue Mouse IgG Type and Titer assay kit, we can identify the IgG isotype, quantify IgG quantity per isotype, and assess cell viability and cell count.
Our Carterra LSA platform enables high-throughput monoclonal antibody characterization. Services include the following:
- High-throughput kinetic screening to determine the binding kinetics (ka and kd) and affinity (KD) of up to 1,152 monoclonal antibodies, 384 clones at a time in parallel, providing essential information for selecting optimal antibody candidates.
- Epitope binning to characterize and group monoclonal antibodies by the epitope region to which they bind, providing important clues about functional inhibition.
- Epitope mapping of monoclonal antibody libraries against an immobilized array of 384 biotinylated peptides to identify the antibody’s binding site on the target antigen at the amino acid level.
- Quantitation of up to 1,152 antibody and protein concentrations from purified samples and cell supernatants in a single assay.
Compared to traditional Western blots, the Wes instrument from ProteinSimple enables faster, high-throughput, reproducible quantitation and analysis of proteins by size using only 3 μL of sample per capillary.
To provide researchers with essential sequence information for downstream antibody engineering, functional optimization and patent applications, we can sequence the antibody variable domain from mouse hybridoma cell lines, produce the recombinant antibody on mouse and human frameworks, and validate binding to the target antigen via flow-based ELISA.
If your objective is to identify new antibodies for immunohistochemistry applications (e.g., companion diagnostics), the Antibody Technology team works closely with the Experimental Histopathology shared resource to deliver and characterize novel antibodies that perform well for IHC.
Image from Balakrishnan A, Goodpaster T, Randolph-Habecker J, et al. Analysis of ROR1 protein expression in human cancer and normal tissues. Clin Cancer Res. 2017 23(12):3061-3071 doi: 10.1158/1078-0432.CCR-16-2083